OLMA.US Olema Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
7.56 USD
Close of Nov 16, 2026
6.24 36.26
Market cap
USD 662M
P/E
-
P/B
1.79x
ROE
-68.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is OLMA.US undervalued?

Graham number

The Graham number of Olema Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Olema Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Olema Pharmaceuticals Inc yet.

Olema Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Olema Pharmaceuticals Inc

Olema Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for breast cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal …

Full company profile